More patients receiving Ozempic 0.5 mg (3.1%) and Ozempic 1 mg (3.8%) discontinued treatment due to gastrointestinal adverse reactions compared to placebo (0.4%). Lower-Burp Alternative Treatments For patients who cannot tolerate semaglutide due to persistent sulfur burps or other gastrointestinal side effects, alternative GLP-1 medications or weight loss medications may offer better tolerability
Tirzepatide may be favored when: Maximum weight loss is the primary goal and cost/insurance isn't a barrier A patient has type 2 diabetes and would benefit from tirzepatide's strong glycemic effects A patient didn't achieve adequate results on semaglutide Semaglutide may be favored when: Cost or insurance coverage strongly favors semaglutide A patient's prescriber has a longer track record of clinical experience with the drug (semaglutide has been used clinically for weight loss for longer) A patient tolerates GLP-1-only therapy well and doesn't need the added GIP effect Neither may be appropriate when: A patient has a personal or family history of medullary thyroid carcinoma or MEN2 syndrome A patient is pregnant, breastfeeding, or planning pregnancy soon A patient has a history of pancreatitis or certain GI conditions, without further evaluation A doctor or obesity-medicine specialist will weigh medical history, current medications, lab work, weight-loss goals, and cost before recommending either drug and will monitor treatment over time, adjusting the plan as needed
These contraindications exist because the risks outweigh potential benefits
Over time, however, the treatment effect of a marginal 30-week regimen dissipated
This vigilance helps prevent any adverse reactions and ensures the therapys effectiveness for conditions such as rheumatoid arthritis, osteoarthritis, or other rheumatic diseases
